RT Journal Article
SR Electronic
T1 Early Detection of Ovarian Cancer in Samples Pre-Diagnosis Using CA125 and MALDI-MS Peaks
JF Cancer Genomics - Proteomics
JO Cancer Genomics Proteomics
FD International Institute of Anticancer Research
SP 289
OP 305
VO 8
IS 6
A1 JOHN F. TIMMS
A1 USHA MENON
A1 DMITRY DEVETYAROV
A1 ALI TISS
A1 STEPHANE CAMUZEAUX
A1 KATHERINE MCCURRIE
A1 ILIA NOURETDINOV
A1 BRIAN BURFORD
A1 CELIA SMITH
A1 ALEKSANDRA GENTRY-MAHARAJ
A1 RACHEL HALLETT
A1 JEREMY FORD
A1 ZHIYUAN LUO
A1 VOLODYA VOVK
A1 ALEX GAMMERMAN
A1 RAINER CRAMER
A1 IAN JACOBS
YR 2011
UL http://cgp.iiarjournals.org/content/8/6/289.abstract
AB Aim: A nested case-control discovery study was undertaken to test whether information within the serum peptidome can improve on the utility of CA125 for early ovarian cancer detection. Materials and Methods: High-throughput matrix-assisted laser desorption ionisation mass spectrometry (MALDI-MS) was used to profile 295 serum samples from women pre-dating their ovarian cancer diagnosis and from 585 matched control samples. Classification rules incorporating CA125 and MS peak intensities were tested for discriminating ability. Results: Two peaks were found which in combination with CA125 discriminated cases from controls up to 15 and 11 months before diagnosis, respectively, and earlier than using CA125 alone. One peak was identified as connective tissue-activating peptide III (CTAPIII), whilst the other was putatively identified as platelet factor 4 (PF4). ELISA data supported the down-regulation of PF4 in early cancer cases. Conclusion: Serum peptide information with CA125 improves lead time for early detection of ovarian cancer. The candidate markers are platelet-derived chemokines, suggesting a link between platelet function and tumour development.